Stem cell study is a field that is very arguable. Debate in the path of stem cell study and the characteristics of general health care are a small number of of the topics looked at by health policy experts and individuals dealing with life-altering diseases like diabetes and migraine. The biggest subject concerned, is the origins of these cells. The supplies of stem cells are assorted. They can originate from adults, umbilical cord blood harvesting, and embryos.

The cure for diabetes may come from the findings of stem cell research. The American Diabetes Association advocates this kind of research, and has lobbied assiduously to procure financing. The American Diabetes Association is also combating restrictions on stem cell research relating to diabetes.

UC Berkeley and Stanford University are two institutions that are coming together on a venture to support collaboration among scientists who perform stem cell research.

Doctors, biologists, chemists, engineers and computer scientists from the two schools formerly cited, are joining forces to talk about their effort and to contributions with students and staff.

Both institutions are extremely involved in embryonic stem cell research that scientists foresee will offer managements or cures for diseases like diabetes, Alzheimer's and Parkinson's.

As a symbol of their new partnership, the campuses aim to reserve space in their stem cell laboratories for stopover researchers who want to use their sabbaticals functioning with colleagues at the other school.

A biotechnology company, VistaGen Therapeutics, Inc., utilizes embryonic stem cell technologies to find and develop new drugs for diabetes, announced an expansive embryonic stem cell research union with Toronto's University Health Network, Canada's leading research hospital, and its stem cell research colleague, the McEwen Centre for Regenerative Medicine.

The fresh union places VistaGen to be able to continue to utilize the embryonic stem cell biology information and innovative embryonic stem cell know-how of Dr. Gordon Keller, one of the world's foremost stem cell researchers and the Director of the McEwen Centre for Regenerative Medicine. VistaGen and Dr. Keller look forward to carrying out research into advanced techniques to differentiate between embryonic stem cells into mature cardiac, liver, and pancreatic beta-islet cells. This will progress VistaGen's industry-leading, in vitro biological systems and bioinformatics databases for prognostic toxicology submissions.

This research program can be seen on the licenses of Dr. Keller which were provided by VistaGen. These licenses were given for the intellectual property of the former embryonic stem cell. These also include research and findings about the recent embryonic stem cells.

VistaGen also is hoping to use the results of this research to develop the next generation of its adapted embryonic stem cell-based heart, liver and pancreatic beta-islet cell differentiation systems for discovering innovative drugs to treat heart disease, liver disease and diabetes.

Still another bunch of researchers from the Spring Point Project has been initiating hard work to offer a cure by inserting insulin-producing islet cells derived from pigs into diabetics. Studies demonstrated that transplanting healthy human islet cells in diabetics could turn around the disease. But because of a lack of human donor organs access is restricted to such cells.

Dr. Bernhard Hering together with his group worked on islet cell transplants from pigs to monkeys. They found out that the cell transplanted to monkey turned out to be a long-term diabetes reversal. Dr. Hering presented presentation in PowerPoint. This presentation included a chart that showed inconsistent counts in the blood sugar up to a certain level in monkeys. This research most especially the use of pig has proved very useful. Some of the areas shown are the bowels in transplants and pig valves. Accordingly, the skin of the pigs can also be used to replace the skin of the human.

Due to the fact that this is introducing foreign cells into a body, those receiving the transplants would have to take medication to make sure they did not reject the cells. There could be side effects, but at this time, it is unknown how serious they could be, and the side effects could vary from patient to patient.

Sooner, the very first experiment on the different severities of diabetes will be clinically tried especially to those who cannot check their blood sugar levels constantly. These people are also those who experience different episodes of the disease.

The controversy on the research about stem cells are yet to end until the status will be different from the present. The issues and controversies may only end if the stem cells will be developed from a specific source.